Observation On The Efficacy Of Concurrent Chemoradiotherapy For Sequential Chemotherapy Combined With Recombinant Human Endostatin For Advanced Cervical Cancer

Object:In this study,we retrospectively analyzed the effects of Endostar degree combined with synchronous radiotherapy and chemotherapy sequential chemotherapy regimen on the efficacy and side effects of mid-late cervical cancer treatment in order to explore whether this regimen can become a new choice of clinical treatment in mid-late cervical cancer,so as to improve the effective rate of treatment.To evaluate the tolerability of this regimen by investigating the increase of adverse reactions compared with standard treatments.Methods:Clinical data of 86 patients with advanced cervical cancer(stage Ⅱb-Ⅳa)who were treated in our hospital(Weihai Municipal Hospital)from January 2014 to December 2018.They were divided into two groups,one part received standard concurrent chemoradiotherapy+sequential chemotherapy(control group)44 cases,another part received concurrent chemoradiotherapy+sequential chemotherapy,chemotherapy concurrently+Endotherapy(study group)42 cases.There was no statistically significant difference in the general data between the two groups(P>0.05).Patients in control group were treated with standard chemoradiotherapy.Three-dimensional adaptive intensity-modulated radiation therapy 5000 cGy/25f was used in vitro,and 3000 cGy/6f was installed after-treatment.The concurrent chemotherapy regimen was docetaxel 75 mg/m2,d1+cisplatin 75 mg/m2,d2,21 d/cycle,and concurrent chemotherapy for 2 cycles.After sequential chemoradiotherapy,sequential chemotherapy was performed for 4 cycles,using docetaxel 75 mg/m2,d1+cisplatin 75 mg/m2,d2,21 d/cycle.Study group received concurrent chemoradiotherapy(radiochemotherapy regimen was the same as that of control group),and the chemotherapy was accompanied by 30 mg of Endostar,d1-7,21d/cycle.Evaluate the results of gynecological examination,pelvic CT/MRI,3 months after the completion of treatment.Take the above examination data as an indicator to compare the short-term efficacy of patients.RECIST criteria are evaluated based on the efficacy of solid tumor treatment.Observe and record the early complications during the treatment and within 3 months after treatment,including hematopoietic function,adverse reactions of digestive system and genitourinary system,cardiac adverse reactions.The clinical efficacy evaluation standards refer to the solid tumor treatment efficacy evaluation standard RECIST.According to CR+PR calculated effective rate(RR),total effective rate=(CR+PR)/total number of patients in this group ×100%.Adverse reaction pairs were graded according to the RTOG criteria for acute radiation injury.Results:The number of patients with complete remission,partial remission,complete remission rate and total effective rate in the study group were significantly higher than those in the control group,and the differences between groups were statistically significant(P<0.05).The total effective rate of squamous cell carcinoma patients in the control group was significantly lower than that in the study group,P<0.05,the difference was statistically significant,while the total effective rate of adenocarcinoma patients in the control group was lower than that in the study group,but P>0.05,there was no statistical significance.The bone marrow of the study group patients The incidence of inhibition of adverse reactions was similar to that of the patients in the control group,P>0.05,and the difference was not statistically significant.The incidence of adverse reactions in the rectum and upper gastrointestinal side reactions in the two groups was compared.There was no difference in the incidence of two adverse reactions of the digestive system between the patients in the control group and P>0.05,and the difference was not statistically significant.The incidence of adverse reactions in the urogenital system of the patients in the study group was not significantly different from that in the control group,P>0.05 The difference was not statistically significant.The incidence of adverse reactions in the two groups of patients was similar,P>0.05,and the difference was not statistically significant.Conclusion:In patients with advanced cervical cancer who have undergone chemoradiotherapy,especially in squamous cell carcinoma,the efficacy of Endostar combined with concurrent chemoradiotherapy is significantly better than that of concurrent chemoradiotherapy alone,without increasing the incidence of adverse reactions.Endostar combined with concurrent chemoradiotherapy can be used as a new clinical treatment method for patients with advanced cervical cance.